Compare AbCellera Biologics Inc (ABCL) vs Kroger Co (KR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Kroger Co — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Kroger Co trades at $59.07 (market cap $35.86B). The key difference: Kroger Co is far larger — about 15.3× AbCellera Biologics Inc's market cap, and Kroger Co pays a 2.46% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KR | |
|---|---|---|
Market Cap | $2.35B | $35.86B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $75.60 |
52-Week Low | $2.78 | $55.53 |
Enterprise Value | $1.99B | $55.96B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Kroger (KR) trades at $58.54, up 0.55% today, with a bearish technical signal but strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. The company announced a $1.65 billion acquisition of Giant Eagle, expanding its Midwest footprint. Cash flow improved in 2025 with net cash flow of $2.08 billion, though net income margin remains thin at 0.71%.
Outlook is cautiously optimistic with a $67.29 price target, but risks include competitive pressures and rising debt. The stock offers growth through strategic acquisitions and dividend hikes, yet faces margin compression and integration challenges from recent deals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
